These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1373 related articles for article (PubMed ID: 12658727)

  • 1. Cholecystokinin-B (CCK-B)/gastrin receptor targeting peptides for staging and therapy of medullary thyroid cancer and other CCK-B receptor expressing malignancies.
    Béhé M; Behr TM
    Biopolymers; 2002; 66(6):399-418. PubMed ID: 12658727
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cholecystokinin-B/Gastrin receptor-targeting peptides for staging and therapy of medullary thyroid cancer and other cholecystokinin-B receptor-expressing malignancies.
    Behr TM; Béhé MP
    Semin Nucl Med; 2002 Apr; 32(2):97-109. PubMed ID: 11965605
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cholecystokinin-B/gastrin receptor binding peptides: preclinical development and evaluation of their diagnostic and therapeutic potential.
    Behr TM; Béhé M; Angerstein C; Gratz S; Mach R; Hagemann L; Jenner N; Stiehler M; Frank-Raue K; Raue F; Becker W
    Clin Cancer Res; 1999 Oct; 5(10 Suppl):3124s-3138s. PubMed ID: 10541353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiolabeled peptides for targeting cholecystokinin-B/gastrin receptor-expressing tumors.
    Behr TM; Jenner N; Béhé M; Angerstein C; Gratz S; Raue F; Becker W
    J Nucl Med; 1999 Jun; 40(6):1029-44. PubMed ID: 10452322
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CCK receptors in human neuroendocrine tumors: clinical implications.
    Reubi JC
    Scand J Clin Lab Invest Suppl; 2001; 234():101-4. PubMed ID: 11713969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cholecystokinin(CCK)-A and CCK-B/gastrin receptors in human tumors.
    Reubi JC; Schaer JC; Waser B
    Cancer Res; 1997 Apr; 57(7):1377-86. PubMed ID: 9102227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Radiolabeling approaches for cholecystokinin B receptor imaging.
    Aloj L; Panico MR; Caracó C; Zannetti A; Del Vecchio S; Di Nuzzo C; Arra C; Morelli G; Tesauro D; De Luca S; Pedone C; Salvatore M
    Biopolymers; 2002; 66(6):370-80. PubMed ID: 12658724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Diagnostic applications of radiolabeled peptides in nuclear endocrinology.
    Behr TM; Béhé M; Becker W
    Q J Nucl Med; 1999 Sep; 43(3):268-80. PubMed ID: 10568142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. 99mTc-labeling and in vitro and in vivo evaluation of HYNIC- and (Nalpha-His)acetic acid-modified [D-Glu1]-minigastrin.
    von Guggenberg E; Behe M; Behr TM; Saurer M; Seppi T; Decristoforo C
    Bioconjug Chem; 2004; 15(4):864-71. PubMed ID: 15264875
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Imaging tumors with peptide-based radioligands.
    Behr TM; Gotthardt M; Barth A; Béhé M
    Q J Nucl Med; 2001 Jun; 45(2):189-200. PubMed ID: 11476170
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preclinical comparison of (111)In-labeled DTPA- or DOTA-bombesin analogs for receptor-targeted scintigraphy and radionuclide therapy.
    Breeman WA; de Jong M; Erion JL; Bugaj JE; Srinivasan A; Bernard BF; Kwekkeboom DJ; Visser TJ; Krenning EP
    J Nucl Med; 2002 Dec; 43(12):1650-6. PubMed ID: 12468515
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting of cholecystokinin-B/gastrin receptors in vivo: preclinical and initial clinical evaluation of the diagnostic and therapeutic potential of radiolabelled gastrin.
    Behr TM; Jenner N; Radetzky S; Béhe M; Gratz S; Yücekent S; Raue F; Becker W
    Eur J Nucl Med; 1998 Apr; 25(4):424-30. PubMed ID: 9553173
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Gastrin and cholecystokinin peptide-based radiopharmaceuticals: an in vivo and in vitro comparison.
    Tornesello AL; Aurilio M; Accardo A; Tarallo L; Barbieri A; Arra C; Tesauro D; Morelli G; Aloj L
    J Pept Sci; 2011 May; 17(5):405-12. PubMed ID: 21351319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical and initial clinical evaluation of 111In-labeled nonsulfated CCK8 analog: a peptide for CCK-B receptor-targeted scintigraphy and radionuclide therapy.
    de Jong M; Bakker WH; Bernard BF; Valkema R; Kwekkeboom DJ; Reubi JC; Srinivasan A; Schmidt M; Krenning EP
    J Nucl Med; 1999 Dec; 40(12):2081-7. PubMed ID: 10616889
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distinct requirements for activation at CCK-A and CCK-B/gastrin receptors: studies with a C-terminal hydrazide analogue of cholecystokinin tetrapeptide (30-33).
    Lin CW; Holladay MW; Barrett RW; Wolfram CA; Miller TR; Witte D; Kerwin JF; Wagenaar F; Nadzan AM
    Mol Pharmacol; 1989 Dec; 36(6):881-6. PubMed ID: 2601685
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 111In-DTPA-D-Phe1-octreotide binding and somatostatin receptor subtypes in thyroid tumors.
    Forssell-Aronsson EB; Nilsson O; Bejegård SA; Kölby L; Bernhardt P; Mölne J; Hashemi SH; Wängberg B; Tisell LE; Ahlman H
    J Nucl Med; 2000 Apr; 41(4):636-42. PubMed ID: 10768564
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improved kinetic stability of DTPA- dGlu as compared with conventional monofunctional DTPA in chelating indium and yttrium: preclinical and initial clinical evaluation of radiometal labelled minigastrin derivatives.
    Béhé M; Becker W; Gotthardt M; Angerstein C; Behr TM
    Eur J Nucl Med Mol Imaging; 2003 Aug; 30(8):1140-6. PubMed ID: 12768330
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unexpected high incidence of cholecystokinin-B/gastrin receptors in human medullary thyroid carcinomas.
    Reubi JC; Waser B
    Int J Cancer; 1996 Sep; 67(5):644-7. PubMed ID: 8782652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current diagnosis and treatment of gastrointestinal carcinoids in a series of 101 patients: the significance of serum chromogranin-A, somatostatin receptor scintigraphy and somatostatin analogues.
    Nikou GC; Lygidakis NJ; Toubanakis C; Pavlatos S; Tseleni-Balafouta S; Giannatou E; Mallas E; Safioleas M
    Hepatogastroenterology; 2005; 52(63):731-41. PubMed ID: 15966194
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of polyglutamic acids to reduce uptake of radiometal-labeled minigastrin in the kidneys.
    Béhé M; Kluge G; Becker W; Gotthardt M; Behr TM
    J Nucl Med; 2005 Jun; 46(6):1012-5. PubMed ID: 15937313
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 69.